These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. P53 Gene Mutation Identified by Next Generation Sequencing in Poorly Differentiated Neuroendocrine Carcinoma of the Nasal Cavity. Wasserman JK; AlGhamdi D; de Almeida JR; Stockley TL; Perez-Ordonez B Head Neck Pathol; 2019 Sep; 13(3):516-522. PubMed ID: 29845478 [TBL] [Abstract][Full Text] [Related]
6. NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas. Meder L; König K; Ozretić L; Schultheis AM; Ueckeroth F; Ade CP; Albus K; Boehm D; Rommerscheidt-Fuss U; Florin A; Buhl T; Hartmann W; Wolf J; Merkelbach-Bruse S; Eilers M; Perner S; Heukamp LC; Buettner R Int J Cancer; 2016 Feb; 138(4):927-38. PubMed ID: 26340530 [TBL] [Abstract][Full Text] [Related]
7. Clinicopathological and genomic features in patients with head and neck neuroendocrine carcinoma. Ohmoto A; Sato Y; Asaka R; Fukuda N; Wang X; Urasaki T; Hayashi N; Sato Y; Nakano K; Yunokawa M; Ono M; Tomomatsu J; Toshiyasu T; Mitani H; Takeuchi K; Mori S; Takahashi S Mod Pathol; 2021 Nov; 34(11):1979-1989. PubMed ID: 34247193 [TBL] [Abstract][Full Text] [Related]
8. Refined criteria for p53 expression in ovarian mucinous tumours are highly concordant with TP53 mutation status, but p53 expression/TP53 status lack prognostic significance. Dundr P; Hájková N; Kendall Bártů M; Cibula D; Drozenová J; Fabian P; Fadare O; Frühauf F; Hausnerová J; Hojný J; Laco J; Lax SF; Matěj R; Méhes G; Michálková R; Němejcová K; Singh N; Stolnicu S; Švajdler M; Zima T; McCluggage WG; Stružinská I Pathology; 2023 Oct; 55(6):785-791. PubMed ID: 37500307 [TBL] [Abstract][Full Text] [Related]
9. Comparison of four DLL3 antibodies performance in high grade neuroendocrine lung tumor samples and cell cultures. Brcic L; Kuchler C; Eidenhammer S; Pabst D; Quehenberger F; Gazdar AF; Popper H Diagn Pathol; 2019 May; 14(1):47. PubMed ID: 31109352 [TBL] [Abstract][Full Text] [Related]
10. Gene Expression Profiling of Lung Atypical Carcinoids and Large Cell Neuroendocrine Carcinomas Identifies Three Transcriptomic Subtypes with Specific Genomic Alterations. Simbolo M; Barbi S; Fassan M; Mafficini A; Ali G; Vicentini C; Sperandio N; Corbo V; Rusev B; Mastracci L; Grillo F; Pilotto S; Pelosi G; Pelliccioni S; Lawlor RT; Tortora G; Fontanini G; Volante M; Scarpa A; Bria E J Thorac Oncol; 2019 Sep; 14(9):1651-1661. PubMed ID: 31085341 [TBL] [Abstract][Full Text] [Related]
11. REST Inactivation and Coexpression of ASCL1 and POU3F4 Are Necessary for the Complete Transformation of RB1/TP53-Inactivated Lung Adenocarcinoma into Neuroendocrine Carcinoma. Masawa M; Sato-Yazawa H; Kashiwagi K; Ishii J; Miyata-Hiramatsu C; Iwamoto M; Kohno K; Miyazawa T; Onozaki M; Noda S; Shimizu Y; Niho S; Yazawa T Am J Pathol; 2022 Jun; 192(6):847-861. PubMed ID: 35367201 [TBL] [Abstract][Full Text] [Related]
12. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome. Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922 [TBL] [Abstract][Full Text] [Related]
13. Frequency of Somatic TP53 Mutations in Combination with Known Pathogenic Mutations in Colon Adenocarcinoma, Non-Small Cell Lung Carcinoma, and Gliomas as Identified by Next-Generation Sequencing. Shajani-Yi Z; de Abreu FB; Peterson JD; Tsongalis GJ Neoplasia; 2018 Mar; 20(3):256-262. PubMed ID: 29454261 [TBL] [Abstract][Full Text] [Related]
14. Expression of p53 and Rb reveal subtypes of gastric neuroendocrine carcinoma with distinct prognosis. Xing J; Chen J; You T; Sun Z; Lu T; Cheng Y; Wu H; Bai C J Neuroendocrinol; 2023 Apr; 35(4):e13257. PubMed ID: 36964649 [TBL] [Abstract][Full Text] [Related]
15. Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D. Simbolo M; Mafficini A; Sikora KO; Fassan M; Barbi S; Corbo V; Mastracci L; Rusev B; Grillo F; Vicentini C; Ferrara R; Pilotto S; Davini F; Pelosi G; Lawlor RT; Chilosi M; Tortora G; Bria E; Fontanini G; Volante M; Scarpa A J Pathol; 2017 Mar; 241(4):488-500. PubMed ID: 27873319 [TBL] [Abstract][Full Text] [Related]
17. Performance of the pattern-based interpretation of p53 immunohistochemistry as a surrogate for TP53 mutations in vulvar squamous cell carcinoma. Kortekaas KE; Solleveld-Westerink N; Tessier-Cloutier B; Rutten TA; Poelgeest MIE; Gilks CB; Hoang LN; Bosse T Histopathology; 2020 Jul; 77(1):92-99. PubMed ID: 32236967 [TBL] [Abstract][Full Text] [Related]
18. p53 protein expression patterns associated with TP53 mutations in breast carcinoma. Anderson SA; Bartow BB; Harada S; Siegal GP; Wei S; Dal Zotto VL; Huang X Breast Cancer Res Treat; 2024 Aug; 207(1):213-222. PubMed ID: 38900212 [TBL] [Abstract][Full Text] [Related]
19. ctDNA in Neuroendocrine Carcinoma of Gastroenteropancreatic Origin or of Unknown Primary: The CIRCAN-NEC Pilot Study. Gerard L; Garcia J; Gauthier A; Lopez J; Durand A; Hervieu V; Lemelin A; Chardon L; Landel V; Gibert B; Lombard-Bohas C; Payen L; Walter T Neuroendocrinology; 2021; 111(10):951-964. PubMed ID: 33099543 [TBL] [Abstract][Full Text] [Related]
20. Primary large-cell neuroendocrine carcinoma of the parotid gland: immunohistochemical and molecular analysis of two cases. Nagao T; Sugano I; Ishida Y; Tajima Y; Munakata S; Asoh A; Yamazaki K; Muto H; Konno A; Kondo Y; Nagao K Mod Pathol; 2000 May; 13(5):554-61. PubMed ID: 10824928 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]